By JOVILAND RITA, GMA News
Published March 2, 2021 3:05pm The Armed Forces of the Philippines (AFP) and its branches on Tuesday conducted separate ceremonial vaccinations where at least 120 medical healthcare workers were inoculated againstCOVID-19. AFP spokesperson Major General Edgard Arevalo said at least 30 personnel are expected to get vaccinated by Sinovac's CoronaVac's vaccine in each health facility. At the Camp Aguinaldo General Hospital, among the first recipients of the shots were Office of Chief Nurse’s chief admin officer Lieutenant Colonel Jacquelyn Cloma, operations officer Major Francis Jan Andrade, and assistant chief nurse Major Dennis Delgado. Meanwhile, at the Manila Naval Hospital, the health facility’s commander, Colonel Puralyn, led the vaccination of Philippine Navy and Philippine Marines personnel.
Published March 2, 2021, 5:31 PM
Three months after PSG jab scandal:
The Armed Forces of the Philippines (AFP) officially started the legal coronavirus disease (COVID-19) vaccination of its personnel on Tuesday, March 2 — three months after it was rocked by a scandal that involved select members of the Presidential Security Group (PSG) getting unregistered and possibly smuggled vaccines.
(Photo by Ishara S. KODIKARA / AFP / FILE PHOTO)
Lt. Gen. Cirilito Sobejana, AFP Chief of Staff, witnessed the vaccination rollout at the Camp General Emilio Aguinaldo Station Hospital in Quezon City where three of its hospital staff took the CoronaVac vaccine from China’s Sinovac Biotech Ltd.
March 02, 2021 THE Armed Forces of the Philippines (AFP) on Tuesday, March 2, 2021, launched its official vaccination program against coronavirus disease 2019 (Covid-19) with the inoculation of over 100 personnel.
The military received 100,000 doses of Sinovac vaccine donated by China, about two months after officials admitted that Presidential Security Group (PSG) personnel illegally received Sinopharm vaccines that were smuggled into the country.
Both the Sinovac and Sinopharm vaccines are from China. The Sinovac vaccine was developed by Sinovac Life Sciences Co. Ltd., a subsidiary of the Nasdaq-listed Sinovac Biotech Ltd., while the Sinopharm vaccine was developed by a subsidiary of state-owned China National Pharmaceutical Group Co. Ltd.